January 20, 2021 – Abbott (Abbott Park, IL) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) revised its National Coverage Determination (NCD) to expand coverage for transcatheter edge-to-edge repair (TEER), also referred to as transcatheter mitral valve repair (TMVr), to include patients with secondary (or functional) mitral regurgitation (MR) resulting from heart failure.
According to Abbott, the decision significantly increases the number of people eligible for insurance coverage for mitral valve repair with MitraClip, enabling broader access to the device.
This is the first and only TEER device approved by the FDA and reimbursed by Medicare for primary mitral regurgitation. The recent decision improves insurance coverage for people with secondary MR who need treatment with MitraClip.